These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

83 related articles for article (PubMed ID: 17591085)

  • 1. Lamivudine for treatment of spontaneous exacerbation and reactivation after immunosuppressive therapy in patients with hepatitis B virus infection.
    Inoue T; Fuke H; Yamamoto N; Ito K; Yutaka KY; Yamanaka ; Shiraki K
    Hepatogastroenterology; 2007; 54(75):889-91. PubMed ID: 17591085
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term follow-up of lamivudine treatment in patients with severe acute exacerbation of hepatitis B e antigen (HBeAg)-positive chronic hepatitis B.
    Wong VW; Wong GL; Tsang SW; Hui AY; Chim AM; Yiu KK; Chan HY; Chan FK; Sung JJ; Chan HL
    Antivir Ther; 2008; 13(4):571-9. PubMed ID: 18672536
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of long-term lamivudine treatment of hepatitis B virus recurrence after liver transplantation.
    Woo HY; Choi JY; Jang JW; You CR; Bae SH; Yoon SK; Yang JM; Choi SW; Han NI; Kim DG
    J Med Virol; 2008 Nov; 80(11):1891-9. PubMed ID: 18814257
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Poor response to 18-month lamivudine monotherapy in chronic hepatitis B patients with IgM anti-HBc and acute exacerbation.
    Chen JJ; Lin CY; Sheu MJ; Kuo HT; Sun CS; Tang LY; Wang SL; Tsai SL
    Aliment Pharmacol Ther; 2006 Jan; 23(1):85-90. PubMed ID: 16393284
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Withdrawal of lamivudine in HBeAg-positive chronic hepatitis B patients after achieving effective maintained virological suppression.
    Yeh CT; Hsu CW; Chen YC; Liaw YF
    J Clin Virol; 2009 Jun; 45(2):114-8. PubMed ID: 19451024
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Selection of precore mutants during lamivudine treatment in patients with chronic hepatitis B.
    Cheong JY; Cho SW; Yoo JH; Hong SP; Kim SO; Yoo WD; Kim JH
    Hepatogastroenterology; 2008; 55(84):1029-33. PubMed ID: 18705323
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A 7-year study of lamivudine therapy for hepatitis B virus e antigen-positive chronic hepatitis B patients in China.
    Yao GB; Zhu M; Cui ZY; Wang BE; Yao JL; Zeng MD
    J Dig Dis; 2009 May; 10(2):131-7. PubMed ID: 19426396
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of entecavir treatment for lamivudine-resistant hepatitis B over 3 years: histological improvement or entecavir resistance?
    Suzuki Y; Suzuki F; Kawamura Y; Yatsuji H; Sezaki H; Hosaka T; Akuta N; Kobayashi M; Saitoh S; Arase Y; Ikeda K; Kobayashi M; Miyakawa Y; Kumada H
    J Gastroenterol Hepatol; 2009 Mar; 24(3):429-35. PubMed ID: 19226381
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of interferon and lamivudine treatment in Japanese patients with HBeAg positive chronic hepatitis B.
    Arase Y; Ikeda K; Suzuki F; Suzuki Y; Kobayashi M; Akuta N; Hosaka T; Sezaki H; Yatsuji H; Kawamura Y; Kobayashi M; Kumada H
    J Med Virol; 2007 Sep; 79(9):1286-92. PubMed ID: 17607775
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term lamivudine therapy reduces the risk of long-term complications of chronic hepatitis B infection even in patients without advanced disease.
    Yuen MF; Seto WK; Chow DH; Tsui K; Wong DK; Ngai VW; Wong BC; Fung J; Yuen JC; Lai CL
    Antivir Ther; 2007; 12(8):1295-303. PubMed ID: 18240869
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Potential and limitations of lamivudine monotherapy in chronic hepatitis B: evidence from genotyping.
    Kennedy PT; Phillips N; Chandrasekhar J; Jacobs R; Jacobs M; Dusheiko G
    Liver Int; 2008 May; 28(5):699-704. PubMed ID: 18433396
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antiviral prophylaxis for chemotherapy-induced reactivation of chronic hepatitis B virus infection.
    Kohrt HE; Ouyang DL; Keeffe EB
    Clin Liver Dis; 2007 Nov; 11(4):965-91, x. PubMed ID: 17981237
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Estimating the future health burden of chronic hepatitis B and the impact of therapy in Spain.
    Idris BI; Brosa M; Richardus JH; Esteban R; Schalm SW; Buti M
    Eur J Gastroenterol Hepatol; 2008 Apr; 20(4):320-6. PubMed ID: 18334876
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A prospective and comparative cohort study on efficacy and drug resistance during long-term lamivudine treatment for various stages of chronic hepatitis B and cirrhosis.
    Nishida T; Kobashi H; Fujioka S; Fujio K; Takaguchi K; Ikeda H; Kawaguchi M; Ando M; Araki Y; Higashi T; Shoji B; Takaki A; Iwasaki Y; Sakaguchi K; Shiratori Y; Yamamoto K
    J Gastroenterol Hepatol; 2008 May; 23(5):794-803. PubMed ID: 18086120
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mutational patterns of hepatitis B virus genome and clinical outcomes after emergence of drug-resistant variants during lamivudine therapy: analyses of the polymerase gene and full-length sequences.
    Enomoto M; Tamori A; Kohmoto MT; Morikawa H; Habu D; Sakaguchi H; Takeda T; Seki S; Kawada N; Shiomi S; Nishiguchi S
    J Med Virol; 2007 Nov; 79(11):1664-70. PubMed ID: 17854034
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Differences of YMDD mutational patterns, precore/core promoter mutations, serum HBV DNA levels in lamivudine-resistant hepatitis B genotypes B and C.
    Pan XP; Li LJ; Du WB; Li MW; Cao HC; Sheng JF
    J Viral Hepat; 2007 Nov; 14(11):767-74. PubMed ID: 17927612
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Loss of hepatitis B surface antigen from the serum of patients with chronic hepatitis treated with lamivudine.
    Kobayashi M; Suzuki F; Akuta N; Hosaka T; Sezaki H; Yatsuji H; Yatsuji H; Kobayashi M; Suzuki Y; Arase Y; Ikeda K; Watahiki S; Iwasaki S; Miyakawa Y; Kumada H
    J Med Virol; 2007 Oct; 79(10):1472-7. PubMed ID: 17705186
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Lamivudine therapy for prevention of chemotherapy-induced reactivation of hepatitis B virus].
    Jia J; Lin F
    Zhonghua Gan Zang Bing Za Zhi; 2004 Oct; 12(10):628-9. PubMed ID: 15504300
    [No Abstract]   [Full Text] [Related]  

  • 19. Early response to lamivudine therapy in clinically non-cirrhotic chronic hepatitis B patients with decompensation.
    Dai CY; Yu ML; Hsieh MY; Lee LP; Hou NJ; Huang JF; Chen SC; Lin ZY; Hsieh MY; Wang LY; Tsai JF; Chang WY; Chuang WL
    Liver Int; 2007 Dec; 27(10):1364-70. PubMed ID: 17900250
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of highly active antiretroviral therapy (HAART) on the natural history of hepatitis B virus (HBV) and HIV coinfection: relationship between prolonged efficacy of HAART and HBV surface and early antigen seroconversion.
    Miailhes P; Trabaud MA; Pradat P; Lebouché B; Chevallier M; Chevallier P; Zoulim F; Trepo C
    Clin Infect Dis; 2007 Sep; 45(5):624-32. PubMed ID: 17682999
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.